CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

This study is evaluating CAR T-cell therapy — a treatment where your own immune cells are genetically reprogrammed to attack cancer — for people with hard-to-treat blood cancers that carry a marker called CD19. **You may be eligible if...** - You are between 18 and 65 years old - You have relapsed or treatment-resistant acute lymphocytic leukemia (B-ALL), large B-cell lymphoma (including DLBCL), or mantle cell lymphoma - Your cancer cells test positive for the CD19 protein - You have received at least 2 previous lines of treatment (for lymphoma) or have relapsed after a stem cell transplant (for leukemia) - Your heart, lungs, liver, kidneys are functioning well enough - Your general health score (ECOG) is 0 or 1 **You may NOT be eligible if...** - Your cancer does not express CD19 - Your organ function is below required levels - Your heart pumping function (ejection fraction) is below 50% - Your blood oxygen level is below 93% without supplemental oxygen - You weigh less than 40 kg or more than 130 kg Talk to your doctor to see if this trial is right for you.